Abstract
Abstract Protein-protein interactions are critical for regulating the activity of translation initiation factors and multitude of other cellular process, and form the largest block of untapped albeit most challenging targets for drug development. 4EGI-1, (E/Z)-2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl) hydrazono)-3-(2-nitrophenyl)propanoic acid, is a hit compound discovered in a screening campaign of small molecule libraries as an inhibitor of translation initiation factors eIF4E and eIF4G protein-protein interaction; it inhibits translation initiation in vitro and in vivo. A series of 4EGI-1-derived thiazol-2-yl hydrazones have been designed and synthesized in order to delineate the structural latitude and improve its binding affinity to eIF4E, and increase its potency in inhibiting the eIF4E/eIF4G interaction. Probing a wide range of substituents on both phenyl rings comprising the 3-phenylpropionic acid and 4-phenylthiazolidine moieties in the context of both E- and Z-isomers of 4EGI-1 led to analogs with enhanced binding affinity and translation initiation inhibitory activities.
Original language | English |
---|---|
Pages (from-to) | 361-377 |
Number of pages | 17 |
Journal | European Journal of Medicinal Chemistry |
Volume | 77 |
DOIs | |
State | Published - 22 Apr 2014 |
Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by a sponsored research agreement from Egenix Inc. and NIH grant #RO1CA121357 to M.C.
Funding
This work was supported by a sponsored research agreement from Egenix Inc. and NIH grant #RO1CA121357 to M.C.
Funders | Funder number |
---|---|
Egenix Inc. | |
National Institutes of Health | |
National Cancer Institute | R01CA121357 |
Keywords
- 4EGI-1
- E/Z-isomerization
- Florescence polarization assay
- Hydrazones
- Inhibitors of protein-protein interaction
- Thiazol-2-yl hydrazones
- Translation initiation
- eIF4F